Biology Reference
In-Depth Information
Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S, Chepenik KP, Waldman
SA (2000) Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 52:375-414
Maurice DH, Palmer D, Tilley DG, Dunkerley HA, Netherton SJ, Raymond DR, Elbatany HS,
Jimmo SL (2003) Cyclic nucleotide phosphodiesterase activity, expression, and targeting cells
in the cardiovascular system. Mol Pharmacol 64:533-546
Mazzu A, Nicholls A, Zinny M (2001) Vardenafil: a new highly selective PDE5 inhibitor, interacts
minimally with nitroglycerin in healthy middle-aged subjects. Int J Impot Res 13(suppl 5):S64
(Abstract)
McVary KT, Monnig W, Camps JL, Young JM, Tseng LJ, van den Ende G (2007a) Sildenafil
citrate improves erectile function and urinary symptoms in men with erectile dysfunction and
lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized,
double-blind trial. J Urol 177:1071-1077
McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, Esler A, Sides
GD, Denes BS (2007b) Tadalafil relieves lower urinary tract symptoms secondary to benign
prostatic hyperplasia. J Urol 177:1401-1407
Michaeli T, Bloom TJ, Martins T, Loughney K, Ferguson K, Riggs M, Rodgers L, Beavo JA,
Wigler M (1994) Isolation and characterization of a previously undetected human cAMP
phosphodiesterase by complementation of cAMP phosphodiesterase deficient Saccharomyces
cerevisiae. J Biol Chem 268:12925-12932
Oger S, Behr-Roussel D, Gorny D, Denys P, Lebret T, Alexandre L, Giuliano F (2007) Relaxation
of phasic contractile activity of human detrusor strips by cyclic nucleotide phosphodiesterase
type 4 inhibition. Eur Urol 51:772-780
Ottensen B, Wagner G, Virag R, Fahrenkrug J (1984) Penile erection: possible role for vasoactive
intestinal polypeptide as a neurotransmitter. Br J Med 288:9-11
Porst H (1996) The rationale for prostaglandin E1 in erectile failure: a survey of worldwide
experience. J Urol 155:802-815
Rajasekaran M, Sikka S, Hellstrom W, Doherty P (1998) Evidence for the presence of the type 4
phosphodiesterase in isolated human cavernosal smoothmuscle cells. Int J Impot Res 10(suppl 3):
S55 (Abstract)
Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ (1992) Nitric oxide as a mediator of
relaxation of the corpus cavernosum in response to non-adrenergic, non-cholinergic neuro-
transmission. N Engl J Med 326:90-94
Roehrborn CG, Marks LS, Fenter T, Freedman S, Tuttle J, Gittleman M, Morril B, Wolford ET
(2004) Efficacy and safety of dutasteride in the four-year treatment of men with benign
prostatic hyperplasia. Urology 63:709-715
Rybulkin SD, Yan C, Bornfeld KE, Beavo JA (2003) Cyclic GMP phosphodiesterase and smooth
muscle function. Circ Res 93:280-291
Saighi D, Zerbib M, Thiounn N, Flam T, Conquy S, Jacob L, dall'Ava-Santucci J, Debr´ B, Dinh-Xuan
AT (2000) In vitro study of the modulation of human ureteral tonus by nitric oxide and zaprinast, a
phosphodiesterase inhibitor. Prog Urol 10:1161-1168
Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC (2002) Sildenafil influences
lower urinary tract symptoms. BJU Int 90:836-839
Silver PJ, Dundore RL, Bode DC, de Garavilla L, Buchholz RA, van Aller G, Hamel LT, Bacon E,
Singh B, Lesher GY (1997) Cyclic GMP potentiation by WIN 58237, a novel cyclic nucleotide
phosphodiesterase inhibitor. J Pharmacol Exp Ther 271:1143-1149
Smet PJ, Edyvane KA, Jonasvicius J, Marshall VR (1994) Colocalisation of nitric oxide synthase
with vasoactive intestinal peptide, neuropeptide Y and thyrosine hydroxylase in nerves sup-
plying the human ureter. J Urol 152:1292-1296
Sommer F, Engelmann U (2004) Future options for combination therapy in the management of
erectile dysfunction in older men. Drugs Aging 21:555-564
Stief C, Porst H, Saenz de Tejada I, Ulbrich E, Beneke M, Vardenafil Study Group (2004)
Sustained efficacy and tolerability with vardenafil over two years of treatment in men with
erectile dysfunction. Int J Clin Pract 58:230-239
